Actively Recruiting
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
Led by Massachusetts General Hospital · Updated on 2026-03-23
500
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.
CONDITIONS
Official Title
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Current age 30-75 years
- Established primary care at Mass General Brigham with at least one visit in the last 2 years
You will not qualify if you...
- Currently taking LDL cholesterol- lowering medications, including statins
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
Research Team
R
Roukoz Karam, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here